Market revenue in 2023 | USD 8,851.4 million |
Market revenue in 2030 | USD 11,102.4 million |
Growth rate | 3.3% (CAGR from 2023 to 2030) |
Largest segment | Primary hypertension |
Fastest growing segment | Secondary Hypertension |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Primary Hypertension, Secondary Hypertension |
Key market players worldwide | Sanofi SA, Boehringer Ingelheim Pharma, Novartis AG ADR, Johnson & Johnson, Daiichi Sankyo Co Ltd, Merck & Co Inc, AstraZeneca PLC, Pfizer Inc, Lupin, Sun Pharmaceutical Industries |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-hypertensive drugs market will help companies and investors design strategic landscapes.
Primary hypertension was the largest segment with a revenue share of 71.54% in 2023. Horizon Databook has segmented the North America anti-hypertensive drugs market based on primary hypertension, secondary hypertension covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America anti-hypertensive drugs market, including forecasts for subscribers. This continent databook contains high-level insights into North America anti-hypertensive drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account